In this context, perifosine, an alkylphospholipid that introduces into the plasma membrane and blocks AKT phosphorylation and signalling by disrupting AKT translocation to the plasma membrane, has displayed potent antitumor effects not only in human tumor models [45] but also in clinical phase I/II trials, where it was highly efficient in patients with advanced STS, including leiomyosarcomas and synovial sarcomas [46]. This evidence concerns the gene AKT1 and synovial sarcoma.